Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $37.4 million.

  • Theravance Biopharma's Total Current Liabilities rose 5962.02% to $37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 5962.02%. This contributed to the annual value of $32.1 million for FY2024, which is 2954.74% up from last year.
  • Latest data reveals that Theravance Biopharma reported Total Current Liabilities of $37.4 million as of Q3 2025, which was up 5962.02% from $54.6 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Total Current Liabilities peaked at $142.1 million during Q3 2022, and registered a low of $21.7 million during Q1 2024.
  • In the last 5 years, Theravance Biopharma's Total Current Liabilities had a median value of $32.1 million in 2024 and averaged $44.8 million.
  • In the last 5 years, Theravance Biopharma's Total Current Liabilities plummeted by 8215.18% in 2023 and then soared by 13809.38% in 2025.
  • Theravance Biopharma's Total Current Liabilities (Quarter) stood at $58.6 million in 2021, then crashed by 50.99% to $28.7 million in 2022, then fell by 13.75% to $24.8 million in 2023, then grew by 29.55% to $32.1 million in 2024, then increased by 16.59% to $37.4 million in 2025.
  • Its Total Current Liabilities was $37.4 million in Q3 2025, compared to $54.6 million in Q2 2025 and $31.5 million in Q1 2025.